The cancer drug revolution just got an upgrade
Between a CRISPR injection that could kill the $500K price tag and an AI vaccine hitting 75% response rates, the economics of cancer treatment are about to break open.
The biggest story is a Nature paper from UCSF that could reshape cancer treatment economics. Researchers used CRISPR nanoparticles to create CAR-T cells directly inside the body — no extraction, no lab, no weeks-long manufacturing. A single injection cured leukemia and myeloma in mice within two weeks, and the in vivo-created cells actually outperformed lab-made ones. Current CAR-T therapy costs $400-500K per patient. If this translates to humans, it drops to the cost of an injection.
AI is accelerating the other bottleneck — picking which tumor mutations to target. At AACR 2026, Evaxion's AI-designed neoantigen vaccine EVX-01 achieved a 75% objective response rate in advanced melanoma combined with pembrolizumab, with 92% of responders still responding at 24 months. The platform predicted which neoantigens would be immunogenic — and 84% of them actually triggered immune responses. Separately, circular RNA is emerging as a superior delivery format: AACR data showed circRNA-encoded neoantigens produced stronger T-cell killing than linear mRNA, signaling a generational shift in vaccine technology.
Meanwhile, drugs already prescribed to millions are showing unexpected anti-cancer effects. A JAMA review covering 1.65 million diabetic patients found that GLP-1 agonists like semaglutide cut pancreatic cancer risk by 59%, liver cancer by 53%, and colorectal cancer by 46%. No RCT has confirmed causation yet, but if it holds, the world's most popular obesity drugs are accidentally running the largest cancer prevention trial in history.
Russia formally signed the decree on April 7: personalized mRNA vaccines, peptide vaccines, and CAR-T therapy are now legally free through public healthcare for 2026-2028. The first NeoOncovac patient — a 60-year-old melanoma patient from Kursk — is reported doing well. Moderna's competing V940 has Phase 3 data expected September 2026, with 3-year results already showing a 49% reduction in recurrence. And an unexpected twist: a 4,407-patient study confirmed that mRNA COVID vaccination near the start of immunotherapy doubles 3-year survival in melanoma and lung cancer.
Numbers, sources, and triggers — in comments ↓
spacefrontiers.org
Nature
In vivo site-specific engineering to reprogram T cells
Nature - Stable and cell-specific transgene expression can be achieved through in vivo site-specific integration of large DNA payloads using a two-vector system of enveloped delivery vehicles and...
8April 8, 2026 1.3K 1 12
